申请人:GE HEALTHCARE LIMITED
公开号:US20150004100A1
公开(公告)日:2015-01-01
Pyridazinone compounds of Formula I: (I) wherein: R′ is alkyl or Ar, optionally substituted with at least one alkyl, halogen, hydroxyl, alkoxy, haloalkoxy, acid, ester, amino, nitro, amide, or alkoxyhalo; 2 R is independently alkyi, alkynyl, ester, amino, amide, acid, aryl, heteroaryl, aminoalkyl, —C(=0)alkyl, —C(=0)aryl, —C(=0)heteroaryl, —C(=0)heterocycloalkyl, —C(=0)heterocycloalkylAr, —C(=0)(CH
2
)
n
halo, —C(═O)(CH
2
)nheterocyclyl, or —SĈAr, optionally substituted with at least one alkyi, alkylhalo, halogen, nitro, aryl, heteroaryl, or heteroaryl(CH
2
)nhalo; R
3
and R
4
are independently hydrogen, alkyi, alkenyl, alkynyl, aryl, heteroaryl; Ar is an aryl, heteroaryl, cycloalkyl, heterocycloalkyl group; n is an integer from 0-10; or a radiolabeled derivative thereof. The compounds are useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.
公式I中的吡啶并酮化合物:(I) 其中:R′是烷基或Ar,可选地被至少一种烷基,卤素,羟基,烷氧基,卤代烷氧基,酸,酯,氨基,硝基,酰胺或烷氧卤代基取代;2R独立地是烷基,炔基,酯,氨基,酰胺,酸,芳基,杂芳基,氨基烷基,-C(= 0)烷基,-C(= 0)芳基,-C(= 0)杂芳基,-C(= 0)杂环烷基,-C(= 0)杂环烷基Ar,-C(= 0)(CH2)n卤代基,-C(═O)(CH2)nheterocyclyl或-SĈAr,可选地被至少一种烷基,烷基卤代基,卤素,硝基,芳基,杂芳基或杂芳基(CH2)n卤代基取代;R3和R4独立地是氢,烷基,烯基,炔基,芳基,杂芳基;Ar是芳基,杂芳基,环烷基,杂环烷基基团;n是0-10的整数;或其放射性标记衍生物。这些化合物可用作阿尔茨海默病中Tau病理学的成像探针。还描述了制备这种化合物的组合物和方法。